|Bid||157.30 x 1000|
|Ask||158.00 x 900|
|Day's range||157.29 - 171.25|
|52-week range||117.34 - 497.49|
|Beta (5Y monthly)||1.21|
|PE ratio (TTM)||9.59|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||284.26|
The COVID-19 vaccine maker is jumping into CAR-M technology with its deal with Carisma Therapeutics.
Novavax (NASDAQ: NVAX) is arriving more than a year after market leaders Pfizer and Moderna to the coronavirus vaccine finish line. Novavax soared 2,700% in 2020. As of today, Novavax's vaccine has won authorization from more than 30 countries.
Moderna (NASDAQ: MRNA) has come a long way in just two years. The biotech company developed one of the leading coronavirus vaccines in about nine months -- and has since made billions of dollars in vaccine revenue and profit.